about
GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.The impact of growth hormone therapy on adult height in noonan syndrome: a systematic reviewMutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humansGlucose does not influence the insulin-like growth factor (JGF) binding to carrier proteins (IGFBPs): analysis of rat and human serum by western ligand blottingHeight velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test?Early retesting by GHRH + arginine test shows normal GH response in most children with idiopathic GH deficiency.Neonatal identification of pituitary aplasia: a life-saving diagnosis. Review of five cases.Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society.Epigenetic changes predisposing to type 2 diabetes in intrauterine growth retardation.Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone.Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre TrialLaboratory tests and measurements in children born small for gestational age (SGA).Adipose Tissue: A Metabolic Regulator. Potential Implications for the Metabolic Outcome of Subjects Born Small for Gestational Age (SGA)Uteroplacental insufficiency down regulates insulin receptor and affects expression of key enzymes of long-chain fatty acid (LCFA) metabolism in skeletal muscle at birthThe Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into Adulthood.A position effect on TRPS1 is associated with Ambras syndrome in humans and the Koala phenotype in mice.Late effects of disturbed IGF signaling in congenital diseases.Postnatal onset of severe growth retardation after in utero exposure to carbamazepine and phenobarbital: a case report.Impact of uteroplacental insufficiency on postnatal rat male gonad.Impact of growth hormone therapy on adult height of children born small for gestational age.Bone age assessment in the workup of children with endocrine disorders.Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment.Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review.Review of growth hormone randomized controlled trials in children with idiopathic short stature.Epigenetic mechanisms elicited by nutrition in early life.Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis.Early Detection, Referral, Investigation, and Diagnosis of Children with Growth Disorders.Functional Significance and Predictive Value of MicroRNAs in Pediatric Obesity: Tiny Molecules with Huge Impact?Predictors of blood pressure at 7-13 years: The "new millennium baby" study.Water Balance and 'Salt Wasting' in the First Year of Life: The Role of Aldosterone-Signaling Defects.Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study.Isolation and characterization of omental adipose progenitor cells in children: a potential tool to unravel the pathogenesis of metabolic syndrome.Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.Brain Magnetic Resonance Imaging as First-Line Investigation for Growth Hormone Deficiency Diagnosis in Early Childhood.Expression and down-regulation by retinoic acid of IGF binding protein-2 and -4 in medium from human neuroblastoma cells.Neuroblastoma and insulin-like growth factor system. New insights and clinical perspectives.Non-Alcoholic Fatty Liver Disease (NAFLD) in children and adolescents with Prader-Willi Syndrome (PWS).Grand challenges in pediatric endocrinology.Long-term safety of growth hormone therapy: still a controversial issue.Insulin-like growth factor-II: new roles for an old actor.
P50
Q26777290-D7E8CB68-CE74-46FA-80E8-743750E729C8Q28087652-11CD0FF5-4BEE-4C3C-9F7B-CF968FA291E8Q28586560-4B137A05-9641-4346-BA81-0E78C1C8E1D7Q28618772-0C71982A-A72A-47C7-82B8-D732D6CE67F1Q30709837-CB12E402-BFFF-443C-B607-AD8F34DD1BC2Q30868115-54116504-999A-4C62-8DF3-5B6808A4DC7EQ30920250-3FBD43DA-5A5A-4353-B084-E71C5C1BC2EDQ34596998-2DCC138E-9193-41D8-94DA-30D3501B2A33Q35971112-74CDDC26-3A9C-4616-B7F8-971797B05AD5Q36177633-A43D572F-BBA2-44F2-BBB9-A7541A4D44BBQ36225138-513B1CDD-B17E-4DA0-B098-425DC5C4C2E5Q36247939-F4276133-025F-43C5-98FA-B79EDB576FDAQ36325762-87A9FC55-DC0E-4AF6-848D-4877ED53D4C6Q36676998-370464FA-6291-4E40-914E-62CEEDB73F5DQ36700200-1AC39888-CFBE-4FFB-8DA3-CEE08AEE7FFCQ36948295-202F1148-1C4E-483C-B806-CD2016C2E209Q36994947-B3FEAF11-04E3-4E9E-A033-C47673A40A40Q37304362-2B9EC0D0-7DE2-4A63-9DBF-ED9962E346A6Q37532362-BCB6A426-D754-4A55-83BF-4A0B7BBB1A07Q37586647-34E8CF94-A0B0-4F5B-A74B-153B2180C48DQ37700077-DCF10D54-80D3-4A0F-A11D-6C02822BB252Q37847587-568AF1EF-83E5-45ED-A3C5-C434D3E46A8EQ37852480-AC1DA3CF-8C2B-46A2-841D-CA8978B20B27Q37930888-FA67D54F-8426-47D4-89C1-CE4366E9DFD6Q37946981-4FBB094A-BF85-4D14-A8ED-255CFD9BCB1FQ38211103-253972A1-4FC5-4005-A2A7-E7833EA19C21Q38800827-51D32149-95AE-43FF-965B-7D0169E292ECQ38830236-C5BCD31C-9A50-4489-8B43-B5A7377B2897Q38885340-36849264-8F99-4033-99B9-F77E13744213Q38947094-D24C2E6C-F1A3-43BF-B8CE-05C51AE02A6BQ38967213-56841BF1-5426-402F-B739-3B79C05981B7Q39785275-96EC5EED-4677-4585-A00C-C112416FB188Q40040192-2882654A-B053-40E9-A8A7-0EE4A255BC14Q40515298-3388F692-E684-43DF-901E-28A0B3412099Q41453063-30D5265C-FA25-4063-BF28-DAD8812B20A5Q41453384-A882C9E2-2297-4D0D-B9E0-4C78D8ECD077Q41623393-9B814F00-5D9A-448B-93B3-93D0FACB4FEFQ41851878-4B3E72F3-6682-4E26-90D6-4EC6B28F56B1Q41854984-1BC22EFC-E30C-4D65-A446-D0EA6DC8993DQ42035390-B925B28F-3A70-4C81-914B-000D60D90C32
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2580-8781
@en
name
Stefano Cianfarani
@ast
Stefano Cianfarani
@en
Stefano Cianfarani
@es
Stefano Cianfarani
@nl
type
label
Stefano Cianfarani
@ast
Stefano Cianfarani
@en
Stefano Cianfarani
@es
Stefano Cianfarani
@nl
prefLabel
Stefano Cianfarani
@ast
Stefano Cianfarani
@en
Stefano Cianfarani
@es
Stefano Cianfarani
@nl
P108
P106
P1153
7006169144
P21
P31
P496
0000-0002-2580-8781